Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients
- PMID: 3703280
- DOI: 10.1212/wnl.36.6.739
Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients
Abstract
We investigated levodopa intravenous infusion rates, plasma concentrations, and clinical responses in 23 parkinsonian patients with a fluctuating response to the drug. There was a linear relationship between rate of levodopa infusion and plasma concentration when carbidopa was coadministered. Minimum-therapeutically effective plasma concentrations of levodopa ranged from 3 to 12 nmol/ml. The duration, but not the magnitude, of clinical response was linearly related to plasma concentrations. The clinical response lagged behind the rise and fall of plasma levodopa. There was no evidence of idiosyncratic pharmacokinetic or pharmacodynamic responses to levodopa to explain the fluctuating response.
Similar articles
-
On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.Ann Neurol. 1987 Oct;22(4):535-40. doi: 10.1002/ana.410220415. Ann Neurol. 1987. PMID: 3324948 Review.
-
The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.Ann Neurol. 1985 Nov;18(5):537-43. doi: 10.1002/ana.410180505. Ann Neurol. 1985. PMID: 4073849
-
Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.Neurology. 1987 Jun;37(6):940-4. doi: 10.1212/wnl.37.6.940. Neurology. 1987. PMID: 3587644
-
Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.J Pharmacokinet Pharmacodyn. 2004 Jun;31(3):243-68. doi: 10.1023/b:jopa.0000039566.75368.59. J Pharmacokinet Pharmacodyn. 2004. PMID: 15518246
-
Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.Neurology. 1992 Jan;42(1 Suppl 1):51-6; discussion 57-60. Neurology. 1992. PMID: 1549202 Review.
Cited by
-
Medication responsiveness of motor symptoms in a population-based study of Parkinson disease.Parkinsons Dis. 2011;2011:967839. doi: 10.4061/2011/967839. Epub 2011 Dec 8. Parkinsons Dis. 2011. PMID: 22191067 Free PMC article.
-
Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease.eNeurologicalSci. 2018 Sep 17;13:8-13. doi: 10.1016/j.ensci.2018.09.003. eCollection 2018 Dec. eNeurologicalSci. 2018. PMID: 30294682 Free PMC article.
-
The preoperative neurological evaluation.Neurohospitalist. 2013 Oct;3(4):209-20. doi: 10.1177/1941874413476042. Neurohospitalist. 2013. PMID: 24198903 Free PMC article. Review.
-
The Human Experience with Intravenous Levodopa.Front Pharmacol. 2016 Jan 6;6:307. doi: 10.3389/fphar.2015.00307. eCollection 2015. Front Pharmacol. 2016. PMID: 26779024 Free PMC article. Review.
-
Sublingual Crushed Levodopa for Parkinson's Disease Management of a Lewy Body Dementia Patient With Dysphagia: A Case Report.Cureus. 2025 May 29;17(5):e85064. doi: 10.7759/cureus.85064. eCollection 2025 May. Cureus. 2025. PMID: 40585751 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical